News | Radiopharm Theranostics

ASX Releases

May 29, 2023

FDA Pre-IND Meeting Supports an IND Application for RAD101

Read more Read more

May 9, 2023

RAD Receives FDA Orphan Drug Designation for Trivehexin (RAD301) in Pancreatic Cancer

Read more Read more

April 17, 2023

RAD Enters into Supply Agreement with Terthera for Terbium-161 Isotope

Read more Read more

March 28, 2023

RAD Invited to Participate in Jefferies Radiopharma Innovation Summit

Read more Read more

March 28, 2023

RAD Receives $1.56M R&D Tax Incentive

Read more Read more

March 27, 2023

RAD and GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia

Read more Read more

MEDIA releases

July 8, 2022

RAD to Start Prostate Cancer Trial, Interview with Financial News Network

Read more Read more

June 28, 2022

World Congress Trivehexin Poster Presentation Shows Encouraging Integrin Data

Read more Read more

May 18, 2022

CEO Riccardo Canevari Updates Investors and Discusses Licensing of a Asset from UCLA

Read more Read more

May 9, 2022

Radiopharm Theranostics panel discusses latest progress and understanding of the radiopharmaceutical sector

Read more Read more

May 6, 2022

Radiopharm continues strong progress and recognition of AVβ6-Integrin in Europe

Read more Read more

April 4, 2022

CEO Riccardo Canevari visits Sydney and discusses the use of radiopharmaceuticals with Financial News Network

Read more Read more

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.